Condition: Oncology · Sponsor: Royal Marsden NHS Foundation Trust
Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.
This description comes directly from the study's public registry record.
Serena Vanzan · 020 3186 5161 · vault@rmh.nhs.uk
Eleanor Carlyle · Renal&Melanoma.researchteam@rmh.nhs.uk
Always discuss trial participation with your own doctor first.
| Royal Marsden Hospital NHS Foundation Trust | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03832062